The use of alteplase, although safe, does not offer clear clinical advantages when mild stroke is non-disabling.
NIHSS
alteplase
intravenous thrombolysis
mild stroke
non-disabling stroke
Journal
Frontiers in neurology
ISSN: 1664-2295
Titre abrégé: Front Neurol
Pays: Switzerland
ID NLM: 101546899
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
04
2023
accepted:
19
06
2023
medline:
2
8
2023
pubmed:
2
8
2023
entrez:
2
8
2023
Statut:
epublish
Résumé
It is unknown whether alteplase is effective and safe in patients with mild acute ischemic stroke (AIS). Determining whether symptoms are "disabling" or not is a crucial factor in the management of these patients. This study aimed to investigate the efficacy and safety of alteplase in patients with mild, non-disabling AIS. We included all consecutive patients admitted for AIS at our institution from January 2015 to May 2022 who presented a baseline NIHSS score of 0-5 and fit the criteria to receive intravenous thrombolysis. In order to select only subjects with non-disabling AIS, we excluded patients who scored more than 1 point in the following NIHSS single items: vision, language, neglect, and single limb. Patients who scored at least 1 point in the NIHSS consciousness item were excluded as well. This study is a retrospective analysis of a prospectively collected database. After the application of the exclusion criteria, we included 319 patients, stratified into patients receiving and not receiving alteplase based on non-disabling symptoms. The two groups were comparable regarding demographic and clinical data. Rates of a 3-month favorable outcome, defined as a 3-month mRS score of 0-1, were similar, being 82.3% and 86.1% in the treated and untreated patients, respectively. Hemorrhagic complications and mortality occurred infrequently and were not affected by alteplase treatment. This observational study suggests that the use of alteplase, although safe, is not associated with a better outcome in highly selected patients with non-disabling AIS.
Identifiants
pubmed: 37528859
doi: 10.3389/fneur.2023.1212712
pmc: PMC10390232
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1212712Informations de copyright
Copyright © 2023 Merlino, Nesi, Vergobbi, Scanni, Pez, Marziali, Tereshko, Sportelli, Lorenzut, Janes, Gigli and Valente.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
J Clin Med. 2020 Mar 12;9(3):
pubmed: 32178336
Front Neurol. 2021 Nov 18;12:760813
pubmed: 34867745
Int J Stroke. 2020 Jun;15(4):429-437
pubmed: 31514684
Stroke. 2013 Mar;44(3):870-947
pubmed: 23370205
Stroke Vasc Neurol. 2018 Jan 5;3(1):22-27
pubmed: 29600004
N Engl J Med. 1991 Aug 15;325(7):445-53
pubmed: 1852179
PLoS One. 2013;8(3):e59420
pubmed: 23527192
Stroke. 2012 Feb;43(2):560-2
pubmed: 22052513
Stroke. 2010 Nov;41(11):2581-6
pubmed: 20814000
Stroke. 2018 Mar;49(3):e46-e110
pubmed: 29367334
Int J Stroke. 2019 Aug;14(6):658-663
pubmed: 30907301
N Engl J Med. 2008 Sep 25;359(13):1317-29
pubmed: 18815396
Acta Neurol Scand Suppl. 2014;(198):37-40
pubmed: 24588505
JAMA. 1995 Oct 4;274(13):1017-25
pubmed: 7563451
Stroke. 2012 Feb;43(2):536-8
pubmed: 21980204
Stroke. 2014 Mar;45(3):765-9
pubmed: 24481972
Stroke. 2010 Apr;41(4):661-6
pubmed: 20185781
Int J Stroke. 2022 Jan;17(1):109-119
pubmed: 33568019
J Stroke Cerebrovasc Dis. 2015 Jun;24(6):1276-81
pubmed: 25906938
Stroke. 2021 Jun;52(6):1995-2004
pubmed: 33947209
Front Neurol. 2022 Apr 08;13:851498
pubmed: 35463124
JAMA. 2018 Jul 10;320(2):156-166
pubmed: 29998337
Cochrane Database Syst Rev. 2003;(3):CD000213
pubmed: 12917889
Eur Heart J. 2013 Jul;34(27):2094-106
pubmed: 23625209
Stroke. 1993 Jan;24(1):35-41
pubmed: 7678184
J Stroke Cerebrovasc Dis. 2012 Nov;21(8):732-6
pubmed: 21531576
PM R. 2019 Sep;11(9):996-1003
pubmed: 30746896
Stroke. 2019 Dec;50(12):e344-e418
pubmed: 31662037
Stroke. 2008 Jun;39(6):1668-74
pubmed: 18309149